Table 1 Characteristics and summary of WGS outcome.
Patient characteristics | |
|---|---|
No° patients | 31 |
Age in years, median (range) | 59 (32–79) |
Male | 18 (58%) |
Female | 13 (42%) |
ECOG performance score | |
0 | 8 (26%) |
1 | 23 (74%) |
Royal Marsden Hospital prognostic score | |
Median | 1 |
0 | 4 (13%) |
1 | 6 (19%) |
2 | 8 (26%) |
3 | 0 (0%) |
Missing | 13 (42%) |
Median number of sites of metastases (range) | 2 (1–5) |
Sites of metastases | |
Lymph nodes | 20 (65%) |
Liver | 14 (45%) |
Bone | 12 (39%) |
Lung | 11 (35%) |
Soft tissue | 10 (32%) |
Other | 4 (13%) |
Brain | 0 (0%) |
Previous systemic treatment | |
Yes | 27 (87%) |
No | 4 (13%) |
Mean number of treatment lines (range) | 2 (0-8) |
Biopsy procedures (n = 31) | |
Biopsy sites | |
Liver | 13 (42%) |
Soft tissue (muscle, fascia) | 7 (23%) |
Lymph nodes | 4 (13%) |
Bone | 2 (7%) |
Lung | 2 (7%) |
Other | 3 (10%) |
Sufficient tumour purity | |
Yes | 29 (94%) |
No | 2 (6%) |
Median time to results in calendar days (range) | 15 (10–42) |
Molecular characteristics (n = 29) | |
Tumour mutational burden | |
Low | 20 (69%) |
High | 9 (31%) |
Microsatellite stable | 28 (97%) |
Microsatellite instability/mismatch repair deficient | 1 (3%) / 2 (7%) |
Homologous recombination deficient | 1 (5%) |
Homologous recombination proficient | 19 (95%) |
Median number of variants in driver genes (range) | 5 (1–76) |
Clinical trial inclusion (n = 31) | |
Patients with at least one actionable biomarkera | 26 (84%) |
Patient who received treatment with matched drug | 11 (35%) |
Median time from biopsy to start treatment in business days (range) | 35 (25–45) |
